Opportunity Information: Apply for PAR 08 123
Apply for PAR 08 123
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Genome Wide Association Analysis of Existing Data Sets for Arthritis and Musculoskeletal and Skin Diseases (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Mar 28, 2008.
- Applicants must submit their applications by Jun 18, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Small businesses For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Independent school districts State governments Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education County governments Native American tribal governments (Federally recognized) Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Genome Wide Association Analysis of Existing Data Sets for Arthritis and Musculoskeletal and Skin Diseases (R01) opportunity (Funding Opportunity Number PAR 08-123) is a National Institutes of Health grant announcement issued through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The central goal is to fund genome-wide association studies (GWAS) that focus on diseases and traits aligned with the NIAMS mission, meaning conditions affecting arthritis and rheumatic disease, bone and muscle biology, and skin-related disorders. A key feature of this announcement is its emphasis on using existing data rather than generating entirely new cohorts or starting new genotyping efforts from scratch. Applicants are expected to leverage already-collected genetic and phenotypic information, including data available through NIH resources like the database of Genotypes and Phenotypes (dbGaP) or comparable repositories and datasets held by other organizations or investigators. In practical terms, the program is meant to help researchers move quickly from available genotypes and well-described clinical or biological traits to statistically rigorous association analyses that can identify genetic variants linked to NIAMS-relevant outcomes.
The funding mechanism is the standard NIH Research Project Grant (R01), which typically supports hypothesis-driven, multi-year research projects with clear aims, analytic plans, and deliverables. The announcement also allows, in certain cases, an alternate pathway for investigators who already hold an active NIAMS R01. If a currently funded NIAMS project has already recruited and phenotyped participants suitable for GWAS and genotype data are already available from earlier work, the investigator may apply via a revision application (historically referred to as a competing supplement). That option is specifically intended to add support for the GWAS analysis component, as long as the submission follows both the budget requirements set in the announcement and the NIH formatting rules for revision applications. This design reflects NIAMS interest in maximizing the value of prior investments in cohort development and phenotyping by enabling more advanced, genome-scale analyses without duplicating work.
In terms of scope and scale, NIAMS projected committing about $1 million per year across fiscal years 2009, 2010, and 2011, with the intention of supporting roughly two to four new projects each year. The announcement makes clear that awards depend on both the availability of appropriated funds and the presence of enough high-quality, competitive applications. The estimated total funding listed for the overall period is about $3 million. The funding instrument type is a discretionary grant, categorized under health research, and associated with CFDA number 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). There is no cost sharing or matching requirement, which is consistent with many NIH research project grants.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities), public and private institutions of higher education, small businesses and other for-profit organizations, and a range of government entities such as city or township governments, county governments, state governments, special district governments, and certain housing authorities. The eligibility language also explicitly includes tribal entities and organizations, including federally recognized tribal governments and other tribal organizations. In addition, the announcement lists several categories that NIH often highlights to encourage a wide applicant pool, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Alaska Native and Native Hawaiian-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), regional organizations, and U.S. territory or possession agencies. Foreign organizations are also indicated as eligible under the announcement’s eligibility notes, which is notable because it opens the door to international groups with appropriate datasets and expertise, subject to NIH policies.
Administratively, the opportunity was posted March 28, 2008, with an original and current closing date of June 18, 2010, and an archive date of July 19, 2010, indicating it is no longer active but remains a useful reference point for how NIAMS has structured GWAS-focused calls around secondary analysis of existing datasets. The full announcement was available through the NIH grants guide at the link provided in the source text. For technical issues accessing or linking to the announcement, the contact listed is the NIH Office of Extramural Research (OER) webmaster email.
FAQs: Genome Wide Association Analysis of Existing Data Sets for Arthritis and Musculoskeletal and Skin Diseases (R01) (PAR 08-123)
What is this grant opportunity?
This is a National Institutes of Health (NIH) funding opportunity announcement titled "Genome Wide Association Analysis of Existing Data Sets for Arthritis and Musculoskeletal and Skin Diseases (R01)." The Funding Opportunity Number is PAR 08-123, and it was issued through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
What is the main goal of PAR 08-123?
The central goal is to fund genome-wide association studies (GWAS) that analyze existing genetic and phenotypic datasets to identify genetic variants associated with diseases and traits aligned with the NIAMS mission.
What research areas does NIAMS consider in-scope for this opportunity?
The opportunity targets conditions and traits relevant to NIAMS, including arthritis and rheumatic disease, bone and muscle biology, and skin-related disorders.
Does this opportunity focus on new data collection or existing data?
A key feature is the emphasis on using existing data rather than creating entirely new cohorts or starting new genotyping efforts from scratch. Applicants are expected to leverage already-collected genetic and phenotypic information.
What types of data sources are mentioned as appropriate for the GWAS analyses?
The announcement highlights existing datasets such as those available through NIH resources like the database of Genotypes and Phenotypes (dbGaP), as well as comparable repositories and datasets held by other organizations or investigators.
What is the intended practical outcome of funding these projects?
The program is intended to help researchers move quickly from available genotypes and well-described clinical or biological traits to statistically rigorous association analyses that can identify genetic variants linked to NIAMS-relevant outcomes.
What is the funding mechanism for this program?
The funding mechanism is the NIH Research Project Grant (R01), which generally supports hypothesis-driven, multi-year research projects with clear aims, analytic plans, and deliverables.
Is there an option for investigators with an existing NIAMS R01 to apply differently?
Yes. In certain cases, an investigator who already holds an active NIAMS R01 may apply via a revision application (historically referred to as a competing supplement) to add support for the GWAS analysis component, provided participants are already recruited and phenotyped and genotype data are already available.
What conditions are described for using the revision application pathway?
The revision option is intended specifically to add support for the GWAS analysis component and must follow both the budget requirements set in the announcement and NIH formatting rules for revision applications.
How much funding did NIAMS project for this initiative?
NIAMS projected committing about $1 million per year across fiscal years 2009, 2010, and 2011, with an estimated total of about $3 million over the overall period described.
How many awards per year were anticipated?
The announcement indicated an intention to support roughly two to four new projects each year, depending on available funds and the number of high-quality, competitive applications.
Are awards guaranteed if an application is submitted?
No. The announcement states that awards depend on the availability of appropriated funds and the receipt of enough high-quality, competitive applications.
Is there any cost sharing or matching requirement?
No. The opportunity states there is no cost sharing or matching requirement.
What is the CFDA number associated with this opportunity?
The associated CFDA number is 93.846, titled "Arthritis, Musculoskeletal and Skin Diseases Research."
How is this funding categorized?
The funding instrument type is a discretionary grant. It is categorized under health research.
Who is eligible to apply?
Eligibility is broad and includes domestic and non-domestic organizations. Eligible applicants include nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities), public and private institutions of higher education, small businesses and other for-profit organizations, and various government entities.
What types of government entities are listed as eligible?
Eligible government entities listed include city or township governments, county governments, state governments, special district governments, and certain housing authorities.
Are tribal entities and tribal organizations eligible?
Yes. The eligibility language explicitly includes tribal entities and organizations, including federally recognized tribal governments and other tribal organizations.
Does the announcement encourage applications from specific institution types?
Yes. It explicitly includes categories NIH often highlights to encourage a wide applicant pool, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Alaska Native and Native Hawaiian-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), regional organizations, and U.S. territory or possession agencies.
Are foreign organizations eligible to apply?
Yes. The eligibility notes indicate that foreign organizations are eligible under the announcement, subject to NIH policies.
When was this opportunity posted?
The opportunity was posted on March 28, 2008.
What were the closing and archive dates?
The original and current closing date was June 18, 2010. The archive date was July 19, 2010.
Is PAR 08-123 still active?
No. Based on the closing and archive dates provided, it is no longer active. It remains as a reference point for how NIAMS has structured GWAS-focused calls centered on secondary analysis of existing datasets.
Where was the full announcement made available?
The full announcement was available through the NIH grants guide at the link provided in the source text.
Who is the contact for technical issues accessing or linking to the announcement?
For technical issues accessing or linking to the announcement, the listed contact is the NIH Office of Extramural Research (OER) webmaster email.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Epidemiology Of Drug Abuse (R01)
Previous opportunity: Symptom Interactions in Cancer and Immune Disorders (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 08 123
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 08 123) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mouse Models Containing Human Alleles Novel Tools to Study Brain Function (R21/R33) Apply for PAR 08 158 Funding Number: PAR 08 158 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01) Apply for PAR 08 160 Funding Number: PAR 08 160 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanisms of Alcohol Induced Tissue Injury (R01) Apply for PA 08 164 Funding Number: PA 08 164 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Secondary Analysis of Existing Alcohol Epidemiology Data (R01) Apply for PA 08 167 Funding Number: PA 08 167 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Secondary Analysis of Existing Alcohol Epidemiology Data (R21) Apply for PA 08 168 Funding Number: PA 08 168 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analysis of Existing Alcohol Epidemiology Data (R03) Apply for PA 08 169 Funding Number: PA 08 169 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Economics of Treatment and Prevention Services for Drug Alcohol Abuse (R21) Apply for PA 08 173 Funding Number: PA 08 173 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Integrative Systems Biology Approaches to Auditory Hair Cell Regeneration (R01) Apply for PA 08 177 Funding Number: PA 08 177 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrative Systems Biology Approaches to Auditory Hair Cell Regeneration (R21) Apply for PA 08 176 Funding Number: PA 08 176 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIDCR Clinical Trial Planning Grant (R34) Apply for PAR 08 195 Funding Number: PAR 08 195 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Clinical Trial Planning Grant (R34) Apply for PAR 08 203 Funding Number: PAR 08 203 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Phase I/II Preliminary Clinical Trials in Communication Disorders (R01) Apply for PAR 08 204 Funding Number: PAR 08 204 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Phase III Definitive Clinical Trials in Communication Disorders (R01) Apply for PAR 08 205 Funding Number: PAR 08 205 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Deep Sequencing and Haplotype Profiling of Mental Disorders (R01) Apply for PA 08 198 Funding Number: PA 08 198 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Addressing the Mental Health Needs of Returning Combat Veterans in the Community (R01) Apply for RFA MH 09 070 Funding Number: RFA MH 09 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Deep Sequencing and Haplotype Profiling of Mental Disorders (Collaborative R01) Apply for PAR 08 199 Funding Number: PAR 08 199 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory/Developmental Projects in Translational Research for Neuromuscular Disease (R21) Apply for PAR 08 228 Funding Number: PAR 08 228 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Translational Research at the Aging/Cancer Interface (TRACI) (R01) Apply for PA 08 230 Funding Number: PA 08 230 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Translational Research at the Aging/Cancer Interface (TRACI) (R21) Apply for PA 08 231 Funding Number: PA 08 231 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NINDS Exploratory/Developmental Projects in Translational Research (R21) Apply for PAR 08 232 Funding Number: PAR 08 232 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 08 123", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.